Key result
Tissue plasminogen activator successfully improved the transmitral gradient in a patient with obstructive mitral valve thrombosis, without embolic or bleeding complications.
Why the study?
Does tissue plasminogen activator treatment improve transmitral gradient in a patient with obstructive thrombosis of a mitral prosthesis?
Case Report (n=1)
Does tissue plasminogen activator treatment improve transmitral gradient in a patient with obstructive thrombosis of a mitral prosthesis?
Thrombolytic therapy with tissue plasminogen activator can be a successful alternative to surgery for obstructive mechanical mitral valve thrombosis, even in critically ill patients with multiorgan dysfunction.
Answers are grounded in this paper and cite their sources.
May support tPA consideration in obstructive mitral valve thrombosis; hypothesis-generating and requires prospective validation.
Prosthetic obstructive thrombosis, being a major emergency, requires the identification of symptoms of heart failure, which are crucial elements in the early diagnosis and initiation of prompt therapeutic management. Adequate clinical, preclinical and instrumental assessment is the key tactic, used both to confirm the diagnosis and to assess the severity of the general condition and the prognosis of survival of the patient with obstructive thrombosis of the valve prosthesis. Prosthetic heart valve thrombosis is a rare but serious complication. Surgery is the first-line therapy in symptomatic obstructive mechanical valve thrombosis, thrombolytic therapy has been used as an alternative to surgical treatment. In this case report we described a 63-year-old woman who had undergone mitral valve replacement operation 11 months ago, presenting to the guard room in an extremely serious general condition, in polyvisceral and polysystemic dysfunction syndrome (MODS). A thrombus was detected on the prosthetic mitral valve with high transmitral gradient by transthoracic echocardiography. Tissue plasminogen activator treatment was administered successfully. The gradient was improved on prosthetic mitral valve and embolic complications or bleeding were not occurred.
No takes yet. Share an insight, caveat, or question.
Lupu et al. (2021) conducted a case report in Obstructive thrombosis of mitral prosthesis (n=1). Tissue plasminogen activator was evaluated on Improvement of transmitral gradient and absence of embolic complications or bleeding. Tissue plasminogen activator successfully improved the transmitral gradient in a patient with obstructive mitral valve thrombosis, without embolic or bleeding complications.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: